A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy

Jeroen Claus; Gargi Patel; Tony Ng; Peter Parker

doi:10.1042/BST20140043

A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy

Jeroen Claus^*, Gargi Patel, Tony Ng, Peter Parker

^*Corresponding author for this work

Cell Imaging

Research output: Contribution to journal › Article › peer-review

26 Citations (Scopus)

Abstract

Specific inhibition of members of the EGFR (epidermal growth factor receptor) family, particularly EGFR and HER2 (human epidermal growth factor receptor 2), are an important therapeutic strategy in many human cancers. Compared with classical chemotherapy, these targeted therapeutics are very specific and initially effective, but acquired resistance against these targeted therapies is a recurring threat. A growing body of recent work has highlighted a pseudokinase in the EGFR family, HER3, and its ligand, NRG (neuregulin flu), to be of importance in models of resistant cancers, as well as in patients. In the present article, we describe some of the roles in which HER3 can mediate acquired resistance and discuss the current efforts to target HER3 itself in cancer.

Original language	English
Pages (from-to)	831-836
Number of pages	6
Journal	Biochemical Society Transactions
Volume	42
Issue number	4
DOIs	https://doi.org/10.1042/BST20140043
Publication status	Published - Aug 2014

Keywords

cancer
drug resistance
epidermal growth factor receptor (EGFR)
human epidermal growth factor receptor 2 (HER2)
human epidermal growth factor receptor 3 (HER3)
kinase inhibition
CLINICAL-PRACTICE GUIDELINES
GROWTH-FACTOR RECEPTOR
BREAST-CANCER CELLS
LUNG-CANCER
FOLLOW-UP
KINASE INHIBITORS
AXL KINASE
ACTIVATION
DIAGNOSIS
ERBB3

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1042/BST20140043

Cite this

@article{cc59f9b02b5f46c6aa6d59b02814c1ba,

title = "A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy",

abstract = "Specific inhibition of members of the EGFR (epidermal growth factor receptor) family, particularly EGFR and HER2 (human epidermal growth factor receptor 2), are an important therapeutic strategy in many human cancers. Compared with classical chemotherapy, these targeted therapeutics are very specific and initially effective, but acquired resistance against these targeted therapies is a recurring threat. A growing body of recent work has highlighted a pseudokinase in the EGFR family, HER3, and its ligand, NRG (neuregulin flu), to be of importance in models of resistant cancers, as well as in patients. In the present article, we describe some of the roles in which HER3 can mediate acquired resistance and discuss the current efforts to target HER3 itself in cancer.",

keywords = "cancer, drug resistance, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), human epidermal growth factor receptor 3 (HER3), kinase inhibition, CLINICAL-PRACTICE GUIDELINES, GROWTH-FACTOR RECEPTOR, BREAST-CANCER CELLS, LUNG-CANCER, FOLLOW-UP, KINASE INHIBITORS, AXL KINASE, ACTIVATION, DIAGNOSIS, ERBB3",

author = "Jeroen Claus and Gargi Patel and Tony Ng and Peter Parker",

year = "2014",

month = aug,

doi = "10.1042/BST20140043",

language = "English",

volume = "42",

pages = "831--836",

journal = "Biochemical Society Transactions",

issn = "0300-5127",

publisher = "Portland Press Ltd.",

number = "4",

}

TY - JOUR

T1 - A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy

AU - Claus, Jeroen

AU - Patel, Gargi

AU - Ng, Tony

AU - Parker, Peter

PY - 2014/8

Y1 - 2014/8

N2 - Specific inhibition of members of the EGFR (epidermal growth factor receptor) family, particularly EGFR and HER2 (human epidermal growth factor receptor 2), are an important therapeutic strategy in many human cancers. Compared with classical chemotherapy, these targeted therapeutics are very specific and initially effective, but acquired resistance against these targeted therapies is a recurring threat. A growing body of recent work has highlighted a pseudokinase in the EGFR family, HER3, and its ligand, NRG (neuregulin flu), to be of importance in models of resistant cancers, as well as in patients. In the present article, we describe some of the roles in which HER3 can mediate acquired resistance and discuss the current efforts to target HER3 itself in cancer.

AB - Specific inhibition of members of the EGFR (epidermal growth factor receptor) family, particularly EGFR and HER2 (human epidermal growth factor receptor 2), are an important therapeutic strategy in many human cancers. Compared with classical chemotherapy, these targeted therapeutics are very specific and initially effective, but acquired resistance against these targeted therapies is a recurring threat. A growing body of recent work has highlighted a pseudokinase in the EGFR family, HER3, and its ligand, NRG (neuregulin flu), to be of importance in models of resistant cancers, as well as in patients. In the present article, we describe some of the roles in which HER3 can mediate acquired resistance and discuss the current efforts to target HER3 itself in cancer.

KW - cancer

KW - drug resistance

KW - epidermal growth factor receptor (EGFR)

KW - human epidermal growth factor receptor 2 (HER2)

KW - human epidermal growth factor receptor 3 (HER3)

KW - kinase inhibition

KW - CLINICAL-PRACTICE GUIDELINES

KW - GROWTH-FACTOR RECEPTOR

KW - BREAST-CANCER CELLS

KW - LUNG-CANCER

KW - FOLLOW-UP

KW - KINASE INHIBITORS

KW - AXL KINASE

KW - ACTIVATION

KW - DIAGNOSIS

KW - ERBB3

U2 - 10.1042/BST20140043

DO - 10.1042/BST20140043

M3 - Article

SN - 0300-5127

VL - 42

SP - 831

EP - 836

JO - Biochemical Society Transactions

JF - Biochemical Society Transactions

IS - 4

ER -

A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this